750 Alfred Nobel Drive
Number 108
Eureka Genomics Corp.
Next-gen sequencing start-up Eureka Genomics says its novel algorithms and data structures are especially effective for the analysis of large sets of short genomic subsequences. The company can analyze sequencing data for non-host genetic material, such as bacteria or viruses. It can also design ultraspecific signature sequences that can be used to detect pathogens or ganisms of interest. In addition to its sequencing service business, Eureka intends to generate novel diagnostics, therapeutic targets and possible vaccines based on microorganisms associated with disease.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
• By
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
• By
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
• By
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.